Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $59.85 (market cap $77.37B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 4.5× Zimmer Biomet Holdings Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| MDLZ | ZBH | |
|---|---|---|
Market Cap | $77.37B | $17.36B |
Sector | Consumer Staples | Health |
52-Week High | $70.75 | $107.71 |
52-Week Low | $51.51 | $79.58 |
Enterprise Value | $97.46B | $24.40B |
Dividend Yield | 3.32% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $59.86, down 1.87% today but maintains a bullish technical signal with strong moving average support. The company reported Q1 2026 EPS of $0.67, beating expectations, and shows consistent revenue growth reaching $38.54B in 2025. Analyst consensus is strongly bullish with a $68.00 price target, representing 13.6% upside potential from current levels.
MDLZ offers stable dividend income and brand strength but faces margin compression risks from input cost inflation. The upcoming Q2 2026 earnings report on July 28, 2026 serves as the next major catalyst. While valuation multiples appear elevated, the company's market leadership and innovation pipeline support long-term growth prospects despite near-term profitability challenges.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
